Publications by authors named "Bright Lipenga"
Background: We assessed persistence of typhoid immunity conferred by Vi polysaccharide-tetanus toxoid (Vi-TT) conjugate vaccine (TCV) four years post-vaccination and immunogenicity of a booster dose of Vi-TT given at age five.
Methods: In 2018, a phase 3 trial of Vi-TT in Malawi randomised children 1:1 to receive Vi-TT or meningococcal capsular group A conjugate vaccine (control). Subsequently, TCV was licensed and recommended in the region.
Article Synopsis
- Vaccine safety and immunogenicity data are crucial for making informed decisions in countries where both HIV and typhoid are prevalent, specifically focusing on HIV-exposed uninfected (HEU) children.
- In a study involving Malawian infants, HEU and HIV unexposed uninfected (HUU) participants received the Vi-tetanus toxoid conjugate vaccine (Vi-TT) at different ages, with safety and immune response monitored after vaccination.
- Results showed that the vaccine was generally safe with mild adverse events, and both HEU and HUU children had strong immune responses, indicating that a single dose of Vi-TT could be effectively introduced in HIV-endemic regions.